Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer
This study uncovers a novel role for Jab1 as an RBP, specifically through interactions between its MPN domain and HRR-related RNAs, regulating RNA stability and maintaining HRR competency. Targeting Jab1 represents a promising strategy to pharmacologically induce HRD and enhance the efficacy of PARPi therapies in TNBC. This combination approach may hold translational value for improving clinical outcomes in patients with TNBC.
Authors
- Dexin Kong (ORCID: https://orcid.org/0000-0002-8064-1435)
- Christophe Nicot (ORCID: https://orcid.org/0000-0001-5927-2869)
- Zhenxing Zhong (ORCID: https://orcid.org/0000-0001-5283-1066)
- Zixiang Yu (ORCID: https://orcid.org/0000-0002-1561-5628)
- Shaolu Zhang
- Yingying Wang (ORCID: https://orcid.org/0000-0001-5622-6234)
- Shanshan Liu (ORCID: https://orcid.org/0000-0002-4195-210X)
- Shengfan Huang
- Xin Peng (ORCID: https://orcid.org/0000-0002-0519-6474)
- Yongzhe Wang (ORCID: https://orcid.org/0000-0002-4014-6958)
- Kailin Wang (ORCID: https://orcid.org/0000-0003-2429-1212)
- François X. Claret
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Ministry of Education (PT)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2025-08-16
- DOI
- https://doi.org/10.1186/s12943-025-02422-7
- Citations
- 3
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 3.14
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Chinese Academy of Medical Sciences
- Natural Science Foundation of Tianjin City
- Tianjin Medical University
- State Key Laboratory of Oncology in South China